CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the...

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Mutations in the p53 tumor suppressor gene are prevalent in human cancers, driving tumor progression and treatment resistance.
• Restoring p53 function as a transcription factor has been a clinical challenge.

Purpose of the Study:

• To identify small molecules capable of restoring the p53 pathway in cancer cells with mutant p53.
• To evaluate the therapeutic potential of identified compounds.

Main Methods:

• A bioluminescence-based transcriptional reporter screen was employed to identify functional small molecules.
• Assays included gene expression analysis (NOXA, DR5, p21), cell death markers (caspases, PARP), and mutant p53 stability studies.
• Proteasome inhibitor MG132 was used to investigate degradation pathways.

Main Results:

• CB002 was identified as a compound that restores p53 function in mutant p53-expressing colorectal cancer cells without harming normal cells.
• CB002 treatment increased endogenous p53 target gene expression and induced cancer cell death.
• NOXA was identified as a key mediator of CB002-induced cell death.
• CB002 decreased mutant p53 stability, suggesting ubiquitin-mediated degradation, and this effect was rescued by MG132.

Conclusions:

• CB002 restores p53 pathway activity and induces cancer cell death by targeting mutant p53 for degradation via the proteasome.
• The compound CB002, which induces tumor cell death through NOXA, shows promise for further development as a cancer therapeutic.